Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 09, 2014 06:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Submits BEKINDA(TM) (RHB-102) European Marketing Authorization Application for Oncology Support

RHB-102, newly branded as BEKINDA™, is a proprietary once-daily oral pill formulation of the antiemetic drug ondansetron The European marketing authorization application (MAA) seeks...
December 02, 2014 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma to Sponsor and Exhibit Its Ongoing Phase III Crohn's Program at the Israeli IBD Society Meeting

TEL-AVIV, Israel, Dec. 2, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an Israeli biopharmaceutical company focused on late clinical-stage drugs for...
December 01, 2014 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma and IntelGenx Announce Acceptance for Review of European Marketing Application for RIZAPORT(TM) for Migraines

The German Federal Institute for Drugs and Medical Devices (BfArM) has validated the European Marketing Authorization Application submitted for RIZAPORT™ (RHB-103) and initiated its formal...
November 10, 2014 07:28 ET | Source: RedHill Biopharma Ltd.

FDA Grants QIDP Fast-Track Designation to RedHill Biopharma's Phase III H. pylori Drug RHB-105

Under the FDA's Generating Antibiotic Incentives Now (GAIN) Act, the Qualified Infectious Disease Product (QIDP) designation allows for additional five years of market exclusivity in addition to...
November 10, 2014 06:30 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Reports Results for the Third Quarter of 2014

A strong cash position of approximately $29 million at the end of the third quarter of 2014, enabling the Company to continue to execute its R&D programs including the three ongoing Phase III...
October 28, 2014 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma to Host Third Quarter 2014 Financial Results Conference Call on November 10, 2014

TEL-AVIV, Israel, Oct. 28, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an Israeli biopharmaceutical company focused on late clinical-stage drugs for...
October 22, 2014 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma to Present at the 20th Annual BIO-Europe International Partnering Conference

TEL-AVIV, Israel, Oct. 22, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an Israeli biopharmaceutical company focused on late clinical-stage...
October 01, 2014 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma and IntelGenx Submit European Marketing Authorization Application for Migraine Drug RIZAPORT(R) (formerly RHB-103)

TEL-AVIV, Israel, Oct. 1, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an Israeli biopharmaceutical company focused on late clinical-stage drugs for...
September 16, 2014 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma to Present at the 14th Annual Biotech In Europe Forum for Global Partnering & Investment

TEL-AVIV, Israel, Sept. 16, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an Israeli biopharmaceutical company focused on late clinical-stage...
September 15, 2014 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma to Present at the 7th Annual BioPharm America International Partnering Conference

TEL-AVIV, Israel, Sept. 15, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an Israeli biopharmaceutical company focused on late clinical-stage...